The rHA 20% product, derived from yeast, is a highly purified alternative to human serum albumin, matching it structurally ...

Shilpa Medicare Ltd announces that the results of its Phase I clinical trials were accepted by Subject Expert Committee ...

Shilpa Medicare's Recombinant Human Albumin 20% (rHA) is derived from yeast and offers a highly purified, structurally and ...

In relation to the successful completion of Phase I clinical trials, Shilpa Medicare Ltd has announced that the Subject ...

Shilpa Medicare has informed that the subject expert committee (Haematology) (SEC) has accepted the results of its Phase I clinical trials for Recombinant Human Albumin (rHA) 20% and granted approval ...

Good evening, and welcome to Dyadic International Q3 2024 Conference Call. Currently, all participants are in a listen-only ...

The studies discovered that favorable nanoparticle-protein interactions can be predicted from machine learning models that ...

Machine learning and supercomputer simulations have been used to investigate how tiny gold nanoparticles bind to blood ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

the albumin market is poised for significant progression. Bovine Serum Albumin to Gain Prominence The bovine serum albumin (BSA) segment will experience considerable growth from 2024 to 2032.